DSS Announces 2025 Fiscal Year Audit Report with Going Concern Qualification
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy DSS?
Source: Newsfilter
- Audit Opinion Disclosure: DSS, Inc. received an audit opinion from HTL International LLC in its 2025 fiscal year report, which includes a 'going concern' qualification, indicating potential financial uncertainties that could impact investor confidence and stock performance.
- Compliance Announcement Requirement: Under NYSE American LLC Company Guide Section 610(b), DSS is required to publicly disclose this audit opinion, although the announcement does not amend the financial statements or annual report for the fiscal year 2025, demonstrating the company's commitment to transparency in compliance.
- Diversified Business Model: DSS operates as a multinational company across various sectors including product packaging, biotechnology, commercial lending, and securities investment management, aiming to unlock value through the development of high-growth subsidiaries and strategic IPOs, despite current audit challenges.
- Forward-Looking Statement Risks: The company notes that forward-looking statements may be subject to various risks and uncertainties, which could lead to actual results differing significantly from expectations, potentially further affecting investor confidence in the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DSS
About DSS
DSS, Inc. is a multinational, public company. The Company operates its business through five divisions: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. The Product Packaging division operates through Premier Packaging Corporation, Inc., which markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through its operating company, American Pacific Bancorp, Inc., which represents its banking and financing business line. The Direct Marketing is specialized in marketing and distributing its products and services through its subsidiary and partner network, using the gig economic marketing strategy as a form of direct marketing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DSS Announces 2025 Fiscal Year Audit Report with Going Concern Qualification
- Audit Opinion Disclosure: DSS, Inc. received an audit opinion from HTL International LLC in its 2025 fiscal year report, which includes a 'going concern' qualification, indicating potential financial uncertainties that could impact investor confidence and stock performance.
- Compliance Announcement Requirement: Under NYSE American LLC Company Guide Section 610(b), DSS is required to publicly disclose this audit opinion, although the announcement does not amend the financial statements or annual report for the fiscal year 2025, demonstrating the company's commitment to transparency in compliance.
- Diversified Business Model: DSS operates as a multinational company across various sectors including product packaging, biotechnology, commercial lending, and securities investment management, aiming to unlock value through the development of high-growth subsidiaries and strategic IPOs, despite current audit challenges.
- Forward-Looking Statement Risks: The company notes that forward-looking statements may be subject to various risks and uncertainties, which could lead to actual results differing significantly from expectations, potentially further affecting investor confidence in the company's future prospects.
See More
Insider at DSS Inc (DSS.US) Plans to Sell $23.06 Million in Common Stock via Form 144
Stock Sale Announcement: DSS Inc. plans to sell 31.94 million shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $23.06 million.
See More
ALSET INC - CLOSING OF DEAL DEPENDENT ON DSS STOCKHOLDER APPROVAL - SEC FILING
- Deal Closing: The ALS ETINC deal is set to close contingent upon shareholder approval.
- SEC Filing: The company has filed necessary documents with the SEC regarding the deal.
See More
ALSET INC - AIL TO PROVIDE $2.45 MILLION LOAN TO DSS FOR CONVERTIBLE NOTE AND WARRANTS TO ACQUIRE 16,554,055 DSS SHARES - SEC FILING
Loan and Securities Details: A company has secured a loan of $2.45 million for convertible notes and warrants, which will halt the purchase of 16,554,055 shares.
Regulatory Filing: The information regarding the loan and share purchase has been disclosed in a SEC filing.
See More
ALSET INTERNATIONAL LIMITED SIGNS SECURITIES PURCHASE AGREEMENT WITH DSS INC ON MARCH 26, 2026 - SEC FILING
- Company Announcement: A company named ALSENT INC has entered into a securities purchase agreement with DSS, Inc.
- Date of Agreement: The agreement was finalized on March 26, 2026, indicating a future transaction.
See More
Impact Biomedical Amends Merger Agreement with Dr Ashleys Bio Labs
- Significant Stock Surge: Impact Biomedical shares soared 86.28% in after-hours trading to $0.77, indicating strong market optimism following the amendment of its merger agreement with Dr Ashleys Bio Labs, reflecting investor confidence in future growth prospects.
- Merger Agreement Amendment: On February 27, Impact Biomedical extended the end date of its Merger and Share Exchange Agreement from March 31, 2026, to July 1, 2026, providing the company with additional time to meet compliance requirements and ensuring a smoother transaction process.
- Share Allocation Details: Under the revised terms, Dr Ashleys Bio Labs will issue 169.5 million ordinary shares to its sole shareholder at closing, representing 94.20% of the total issued shares, which will significantly impact the company's equity structure and potentially enhance its market appeal.
- Market Performance Analysis: Despite the recent stock rebound, Impact Biomedical's market capitalization stands at $43.24 million, with a 71.30% decline over the past 12 months, indicating that the company requires clear recovery signals to regain investor confidence and attract capital inflows.
See More
DSS Announces 2025 Fiscal Year Audit Report with Going Concern Qualification
- Audit Opinion Disclosure: DSS, Inc. received an audit opinion from HTL International LLC in its 2025 fiscal year report, which includes a 'going concern' qualification, indicating potential financial uncertainties that could impact investor confidence and stock performance.
- Compliance Announcement Requirement: Under NYSE American LLC Company Guide Section 610(b), DSS is required to publicly disclose this audit opinion, although the announcement does not amend the financial statements or annual report for the fiscal year 2025, demonstrating the company's commitment to transparency in compliance.
- Diversified Business Model: DSS operates as a multinational company across various sectors including product packaging, biotechnology, commercial lending, and securities investment management, aiming to unlock value through the development of high-growth subsidiaries and strategic IPOs, despite current audit challenges.
- Forward-Looking Statement Risks: The company notes that forward-looking statements may be subject to various risks and uncertainties, which could lead to actual results differing significantly from expectations, potentially further affecting investor confidence in the company's future prospects.
See More
Insider at DSS Inc (DSS.US) Plans to Sell $23.06 Million in Common Stock via Form 144
Stock Sale Announcement: DSS Inc. plans to sell 31.94 million shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $23.06 million.
See More
ALSET INC - CLOSING OF DEAL DEPENDENT ON DSS STOCKHOLDER APPROVAL - SEC FILING
- Deal Closing: The ALS ETINC deal is set to close contingent upon shareholder approval.
- SEC Filing: The company has filed necessary documents with the SEC regarding the deal.
See More
ALSET INC - AIL TO PROVIDE $2.45 MILLION LOAN TO DSS FOR CONVERTIBLE NOTE AND WARRANTS TO ACQUIRE 16,554,055 DSS SHARES - SEC FILING
Loan and Securities Details: A company has secured a loan of $2.45 million for convertible notes and warrants, which will halt the purchase of 16,554,055 shares.
Regulatory Filing: The information regarding the loan and share purchase has been disclosed in a SEC filing.
See More
ALSET INTERNATIONAL LIMITED SIGNS SECURITIES PURCHASE AGREEMENT WITH DSS INC ON MARCH 26, 2026 - SEC FILING
- Company Announcement: A company named ALSENT INC has entered into a securities purchase agreement with DSS, Inc.
- Date of Agreement: The agreement was finalized on March 26, 2026, indicating a future transaction.
See More
Impact Biomedical Amends Merger Agreement with Dr Ashleys Bio Labs
- Significant Stock Surge: Impact Biomedical shares soared 86.28% in after-hours trading to $0.77, indicating strong market optimism following the amendment of its merger agreement with Dr Ashleys Bio Labs, reflecting investor confidence in future growth prospects.
- Merger Agreement Amendment: On February 27, Impact Biomedical extended the end date of its Merger and Share Exchange Agreement from March 31, 2026, to July 1, 2026, providing the company with additional time to meet compliance requirements and ensuring a smoother transaction process.
- Share Allocation Details: Under the revised terms, Dr Ashleys Bio Labs will issue 169.5 million ordinary shares to its sole shareholder at closing, representing 94.20% of the total issued shares, which will significantly impact the company's equity structure and potentially enhance its market appeal.
- Market Performance Analysis: Despite the recent stock rebound, Impact Biomedical's market capitalization stands at $43.24 million, with a 71.30% decline over the past 12 months, indicating that the company requires clear recovery signals to regain investor confidence and attract capital inflows.
See More
